아이진

185490KOSDAQ자연과학 및 공학 연구개발업

61.1 / 100

Reference Date: 2026-06-10

Financial Score23.5 / 40

News Sentiment20.6 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Rose 10.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Ajin is a biotech venture company focused on R&D in medicine and pharmacy, specializing in the development of next-generation innovative therapies such as mRNA-based vaccines and AAV gene therapies. The company is also advancing revenue-generating projects, including meningococcal vaccines and botulinum toxin development, while investing in promising ventures to secure key technologies.

Number of Employees

49people

Average Salary

58.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

1.16Industry Average 3.247.0Point

Half of industry avg (excellent)

ROE

-36.31Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

7.00Industry Average 7.314.0Point

In line with industry avg

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲38.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -30.8% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
아이진, 한타바이러스 mRNA 백신 개발 기대감에 ‘급등’ [Why 바...
아이진의 주가가 한타바이러스 mRNA 백신 개발 기대감으로 급등했다.
Positive
아이진, 한타바이러스 백신 국산화 추진
아이진이 한타바이러스 백신 개발에 대한 국가 과제 선정으로 인해 긍정적인 투자 전망을 받고 있다.
Positive
아이진, 한타바이러스 백신 개발 정부과제 선정 소식에 '급등'
아이진의 한타바이러스 mRNA 백신 개발 과제 선정으로 인해 급등했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 1,460Won52-week high 3,22252-week low 1,193

1-month return5.0Point

1m +10.52% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-05-15
Neutral분기보고서 (2026.03)2026-05-15